Navigation Links
Onyx Pharmaceuticals Presents Carfilzomib Data at 53rd American Society of Hematology Annual Meeting
Date:12/12/2011

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced final results from a Phase 2 study, known as the 004 study, evaluating single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and/or refractory multiple myeloma. Results on prolonged infusion of carfilzomib and speed of response were also announced. These data were presented at the 53rd American Society of Hematology (ASH) Annual Meeting in San Diego, CA.

Abstract #813: Final Results from the Bortezomib-Naive Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma
Results from the 004 Phase 2 study evaluated single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who had received one to three prior treatments and had not been previously treated with bortezomib. In 67 evaluable patients, carfilzomib achieved an overall response rate (ORR) of 52 percent and a clinical benefit rate (CBR) of 64 percent when administered at 27mg/m(2). Sixty-four percent of patients were refractory to their most recent therapy prior to entering the trial. Overall response is defined as a partial response or greater.[i]  The median time-to-progression (TTP), duration of response (DOR) and overall survival (OS) were not reached in this study, designed to provide patients with up to 12 cycles of carfilzomib.  Forty-two percent of patients completed greater than 10 cycles and 22 patients continued treatment beyond one year in the extension protocol PX-171-010.

"This Phase 2 study demonstrates promising single-agent activity of carfilzomib in patients with relapsed and/or refractory multiple myeloma who have not been previously treated with bortezomib," said Ravi Vij, M.D., Associate Professor, Department of Medicine,
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... SCOTTSDALE, Ariz. , Dec. 17, 2014 /PRNewswire/ ... of state-of-the-art interactive music products, today announced that ... Ltd, a leading manufacturer and supplier of innovative ... As part of the agreement, RSL ... Facility bundled solution specifically configured for use within ...
(Date:12/17/2014)... BUENA, N.J. , Dec. 17, 2014  IGI ... announced today the closing of its offering of $125 ... due 2019 (the "Notes").  The Notes were offered and ... 144A under the Securities Act of 1933, as amended ... at a fixed rate of 3.75% per year, payable ...
(Date:12/17/2014)... 17, 2014 PCCA received the Autism ... http://bit.ly/1382OkS ) program seal for best practices in ... highlights medical practices, materials and goods that meet ... Children affected by autism often have unique ... by ingredients found in food and medicine – ...
Breaking Medicine Technology:Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3
... Jan. 27, 2011 Significant flooding occurred in many ... January 2011.  Thousands of residents were affected.  A disaster ... on 29 December 2010, by Premier of Queensland, Anna ... in to help their fellow citizens clean-up in the ...
... China and ROCKVILLE, Md., Jan. 26, 2011 /PRNewswire-Asia/ -- Synutra ... formula company in China and a producer, marketer and seller ... that it plans to release its financial results for the ... 2011 after market close. The Company will ...
Cached Medicine Technology:DSM Joins International Response to Flooding in Australia 2DSM Joins International Response to Flooding in Australia 3Synutra to Announce Third Quarter Fiscal 2011 Financial Results 2
(Date:12/21/2014)... As testosterone therapy lawsuit filings ... and blood clots from using testosterone products such as ... shows that the male hormone testosterone may increase the ... published in the Proceedings of the National Academy of ... group of male rats with naturally occurring colon cancer. ...
(Date:12/20/2014)... 21, 2014 BambooIndustry.com is ... the business has announced its bamboo flooring promotion ... best material from certified suppliers, and offers the ... worldwide. In the current promotion, all customers can ... when they say they know BambooIndustry.com from press ...
(Date:12/20/2014)... DePuy Pinnacle hip lawsuits ( ... the artificial hip system was defectively designed continue ... Bernstein Liebhard LLP reports. According to an Order ... on December 2nd, counsel in 10 DePuy Pinnacle ... on November 19, 2014, with depositions to conclude ...
(Date:12/20/2014)... Angeldress.co.uk, the distinguished wedding dress manufacturer and ... fans. The company has recently updated its official blog ... holiday season, Angeldress Blog has recommended some ... Angeldress.co.uk prides itself in offering a huge selection of ... the company’s outfits are very carefully selected based on ...
(Date:12/20/2014)... Viejo, California (PRWEB) December 20, 2014 ... announced the release of a new plugin for Final ... Film Studios. , “TranSlice Volume 5 allows users to ... hand draw it.” Said Christina Austin, CEO of Pixel ... add level of professionalism while maintaining an easy to ...
Breaking Medicine News(10 mins):Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4Health News:Eco-friendy Bamboo Flooring Manufacturer BambooIndustry.com Introduces Its Bamboo Flooring Promotion for 2015 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4Health News:Trendy Professional Wedding Apparel Recommended by Angeldress Blog 2Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2
... safeguards and NHS red tape following the Alder Hey ... according to researchers//. With restrictions on approaching study volunteers, ... many doctors have been deterred from getting studies up ... at Leeds University said, "That's a disaster and it ...
... tiny particles in the air is inhaled, University of ... , nano-sized particles quickly traverse the pathway and make ... is published in the August issue of Environmental Health ... which the researchers found, that could signal inflammation and ...
... supermarkets in UK, namely Tesco, Sainsbury’s, and Asda have decided ... supermarkets have announced deadlines for removing hydrogenated oil, which is ... It has been explained that trans fatty acid or trans ... risk of obesity and heart disease, and has also been ...
... routine pregnancy examinations to check a baby is in a ... researchers have explained that simple palpation, which is the feeling ... cases of abnormal lie, where in a baby is not ... is very important for a doctor to know the lie ...
... knowledge that breast-feeding gives babies the best start in ... are breast-fed beyond none months are prone to allergy.// ... months is known to offer protection against allergies like ... months may increase the risk of developing allergies rather ...
... and Drug Administration has approved a drug called Famvir as ... //The drug is manufactured by Novartis Pharmaceuticals Corp and is ... ,The drug can be consumed as 1,000 milligrams doses twice ... herpes and this drug does not do so, but relieves ...
Cached Medicine News:Health News:Medical researchers being stifled by NHS Red tape 2Health News:Nano-sized inhaled particles traverse quickly from nose to brain 2Health News:Supermarket Chains In UK To Ban The Use Of Trans Fats 2Health News:Researchers Warn That Routine Physical Examination Could Miss Breech Presentation 2
A simple testing set for prescribing aspheric spectacle magnifiers. Redi-glaze lenses are available for instant dispensing which are cut and edged to fit our standard LVA frame....
... to 20 tilting tower ... the vertical, horizontal and ... option to offset the ... ,Filters include Cobalt blue; ...
With a high lens and filter range this ophthalmoscope is ideal for the Primary Care Specialist...
... Halberg Trial Clips have become ... refractive stand., ,These useful and ... over your patient's spectacle frame. ... three lenses and the rubber ...
Medicine Products: